The clinical utilization of SNIP1 and its pathophysiological mechanisms in disease
Yinzhong Chen,
Wei Guo,
Xiucheng Guo,
Qiao Wanqing,
Zongsheng Yin
Affiliations
Yinzhong Chen
Department of Orthopedics, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China; Department of Orthopedics, the Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China
Wei Guo
Department of Medical Imaging, the Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China
Xiucheng Guo
Department of Orthopedics, the Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China
Qiao Wanqing
Department of Orthopedics, the Second Affiliated Hospital of Shandong First Medical University, Tai'an, Shandong, China
Zongsheng Yin
Department of Orthopedics, the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China; Corresponding author. Department of Orthopedics, the First Affiliated Hospital of Anhui Medical University, No. 218, Jixi Road, Hefei, Anhui, China.
Smad intranuclear binding protein 1 (SNIP1), a highly conserved nuclear protein, functions as a transcriptional regulator and exerts a significant influence on disease progression. In addition, the N-terminal domain of SNIP1 facilitates its interaction with Smad4, a signaling protein associated with the TGF-β family, and RelA/p65, a transcription factor connected to NF-κB. This interaction further enhances the transcriptional activation of c-Myc-dependent genes. Presently, the primary emphasis in research is directed towards targeting the catalytic domain of SNIP1, as it holds promise as a potential therapeutic target for various diseases. While the significance of SNIP1 in pathological mechanisms remains uncertain, this review aims to comprehensively examine the existing literature on the association between SNIP1 and proteins implicated in the regulation of diverse clinical conditions, including cancer, inflammation, and related diseases.
